Conext

Raised $10.1M in a Series C round, announced 16 March 2026.

Latest round Series CCountry South KoreaSector Health

Round

Funds CNT201 development, an Australian Phase 2 trial and Phase 3 manufacturing prep.

Amount: $10.1M
Stage: Series C
Announced: 16 March 2026
Lead: Premier Partners
Other investors: Murex Partners, Suin Investment Capital, The Next Lab, Pharmaresearch, ES Investor
Use of funds: Funds CNT201 development, an Australian Phase 2 trial and Phase 3 manufacturing prep.
Checked: Amount and date checked against the press source
Source: Conext (코넥스트) raises ₩15B Series C venturesquare.net

Clinical-stage biotech making recombinant protein drugs, lead CNT201

How much has Conext raised?

Conext raised $10.1M in a Series C round, announced on 16 March 2026.

Who invested in Conext?

Premier Partners led. Investors include Premier Partners, Murex Partners, Suin Investment Capital, The Next Lab, Pharmaresearch and ES Investor.